|
|
 |
| |
addresses the strategic business implications of Medicare for pharmaceutical manufacturers, with a focus on changes set in motion by the Medicare Modernization Act of 2003.
The research enables proactive strategies for working with managed care organizations, pharmacy benefit managers, long-term care facilities, group purchasing organizations, and assisted living facilities.
 View our 2010 Managed Medicare Rx research schedule.
View our 2011 Managed Medicare Rx research schedule.
|
Subscribing Companies Receive
- Customized onsite briefings
- Inquiry privileges—ask the questions you need to put the information to work
- Print copies of research reports & access via a customized website for your company
Contact Managed Medicare Rx
|
| Managed Medicare Rx Publications |
2011
PDP and MA-PD Response to PPACA Part D Changes
Coming March 2011
This report addresses the changes to Medicare Part D brought on by The Patient Protection and Affordable Care Act (PPACA) and how they will affect both plans and pharmaceutical companies. This research will identify innovative contracting strategies resulting from these changes in Medicare Part D that can create a win-win for plans and pharma.
MA-PD and PDP Profiles - 2011
Coming June 2011
This research builds upon the in-depth plan analyses conducted in previous years and will identify and evaluate all of the major Part D (MA-PD and PDPD) players and provide a profile of each along with an assessment of the plans’ strategic response to healthcare reform.
Evolution of Medicare - 2011
Coming September 2011
This forward-looking analysis of Medicare will provide a detailed look at how key players may be affected by and will respond to the new healthcare market environment in the next five years. This research is an update to our 2010 report.
Senior Tracking Study - 2011
Coming November 2011
In-depth view into senior perceptions of the changes enacted by healthcare reform and their behaviors over time as the Medicare D benefit has evolved.
2010
In the 2010 Call Letter for Medicare Advantage and Prescription Drug
Plans, CMS requires plans to focus on managing seven core chronic
diseases. This report will survey leading MA-PDs and PDPs in order to both determine plans' areas of focus and identify best practices of plan/pharma partnerships. It will also provide guidance to pharma on how to best
to engage plans to help ensure that their products are a part of robust
MTM, DSM, and CCIP CMS and the Congress are seeking standardized quality measures that
determine if care is accurate, reliable, and relevant in a patient-centered
way. This report will explore the leading public, quasi-public and private organizations which are influencing the design, development and implementation of quality and outcomes measures which will likely be used to make reimbursement
and coverage determinations in the future. Evolution of Medicare 2010
Coming September 2010
This update to our 2008 research will identify further trends and future direction of Medicare
Senior Tracking Study 2010
Coming November 2010
This research provides in-depth analysis of how consumers view their Part D benefits and how their consumption changes while navigating the complex Medicare benefits
2009
This report examines how employers, facing rising retiree healthcare costs and new regulations affecting the reporting of these healthcare liabilities, will manage their retiree benefits/benefit structure in the future, now that Medicare D is an option. The research explores the evolving management of
specialty drugs, infusion drugs and vaccines under Parts A, B and D of Medicare. Further, it and assesses the regulatory reimbursement criteria and potential alternative pricing structures for products in these drug classes. This research provides in-depth analysis of how consumers view their Part D benefits and how their consumption changes while navigating the complex Medicare benefits This update to our 2008 research will identify further trends and future direction of Medicare
|
|
